 |
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
|
Overview SelectX Pharmaceuticals, Inc. is rapidly establishing itself as a leader in the innovation and application of Genetic Chemistry for small molecule drug discovery. The Company focuses its discovery and development efforts on antimicrobial and other therapeutics that address unmet medical needs. SelectX's most advanced program is a preclinical aminoglycoside antibiotic that addresses the rapidly growing gram negative hospital infection market. A second program focuses on inflammation. SelectX has developed two complementary technologies – Directed Discovery™ and ComGene™ – to implement and exploit the full potential of its Genetic Chemistry platform. A second platform – DART™ (Drug and Antibiotic Resistance prediction Technology) – permits the characterization of drug resistance prior to its clinical emergence, allowing the development of the most durable antibiotics. Business Strategy SelectX's business strategy is to rapidly develop a high potential development pipeline through both proprietary and partnered programs with leading pharmaceutical and biotechnology companies. The value of the Company's technologies resides, in part, in the capability of these technologies to significantly reduce both the time and cost of drug development; provide high-potential lead compounds and drug candidates; and are broadly applicable for the discovery of a wide range of therapeutics. |
SelectX Pharmaceuticals, Inc. |